Drug
Andamertinib clinical trials
Also written PLB1004.
- studies test it
- 11
- open now
- 9
- in phase 3
- 2
- first study started
- 2020
Keep track of what changes. Save the andamertinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2023 (3)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 7
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 1
Avistone Biotechnology Co., Ltd. (8) · Fudan University (1) · Beijing Pearl Biotechnology Limited Liability Company (1) · Avistone Pharmaceutical（Ningbo）Co., LTD. (1)
Often tested with
Tested in the same studies.
Vebreltinib (3) · Anlotinib (1) · C-Met Inhibitor ANS014004 (1)
Studies
Open first, then newest update. How each study uses andamertinib is read from its arms, and is right about nine times in ten.
Testing it · 11
- The Study Of Andamertinib Plus Anlotinib In Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerNot yet recruitingPhase 2Fudan UniversityNCT07780578Written as Andamertinib
- Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.Enrolling by invitationPhase 3Avistone Biotechnology Co., Ltd.NCT06281964Written as PLB1004
- Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR MutationsRecruitingPhase 2Avistone Biotechnology Co., Ltd.NCT07336732Written as PLB1004
- A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung CancerNot yet recruitingPhase 1/2Beijing Pearl Biotechnology Limited Liability CompanyNCT07285148Written as ANS014004 + PLB1004
- Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positiveNot yet recruitingPhase 1/2Avistone Pharmaceutical（Ningbo）Co., LTD.NCT07063329Written as PLB1004 80mg/160mg/240mg oral once daily Combined with Platinum-Based Chemotherapy
- Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI FailureNot yet recruitingPhase 3Avistone Biotechnology Co., Ltd.NCT06970782Written as PLB1004
- Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKIRecruitingPhase 1/2Avistone Biotechnology Co., Ltd.NCT06343064Written as PLB1004
- Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.RecruitingPhase 2Avistone Biotechnology Co., Ltd.NCT06574347Written as PLB1004
- A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung CancerRecruitingPhase 1Avistone Biotechnology Co., Ltd.NCT06046495Written as PLB1004
- A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)Active, not recruitingPhase 2Avistone Biotechnology Co., Ltd.NCT06015503Written as PLB1004
- Assessing the Safety and Efficacy of PLB1004 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)Status unknownPhase 1Avistone Biotechnology Co., Ltd.NCT05347628Written as PLB1004
Codes
What other systems call andamertinib · ClinicalTrials.gg INT015142
- UNII (FDA) 5X3KAG7ZBWANDAMERTINIBOne source FDA
- NCI Thesaurus C209347AndamertinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 5X3KAG7ZBW | ANDAMERTINIB | One source FDA |
| NCI Thesaurus | C209347 | Andamertinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.